3Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008 [ J]. CA Cancer J Clin, 2008, 58(2) : 71-96.
4Shenton KC, Dowsett M, Lu Q, et al. Comparison of biochemical aromatase immunohistochemistry in human breast carcinomas [J]. Breast Cancer Res Treat, 1998,49( suppl 1 ) S101-107 ; 109-119.
5Zhang Z, Yamashita H, Toyama T, et al. Semi-quantitative immunohistochemical analysis of aromatase expression in ductal carcinoma in situ of the breast [ J]. Breast Cancer Res Treat, 2002, 74 ( 1 ) : 47-53.
6Folkman J. Tumor angiogenesis : thrapeutic implication [ J ]. N Engl J Med, 1971, 285(21) : 1182-1186.
7Giatromanolaki A, Sivridis E, Brekken R, et al. The angiogenic “vascular endothelial growth factor/flk-1 (KDR) receptor” pathway in patients with endometrial carcinomal: prognostic and therapeutic implications[J]. Cancer, 2001, 92 (10): 2569-2577.
8Nelson NJ . Angiogenesis research is on fast forward [ J ]. J Natl Cancer Inst, 1999, 91 (10) : 820-822.
9Boehm-Viswanathan T. Is angiogenesis inhibition the Holy Grail of cancer therapy[ J]. Curr Opin Oncol, 2000, 12 (1) : 89-94.
10Proniewska-Skretek E, Mariak Z. Tumor angiogensis in uveal melanoma. Role of vascular endothelial growth factor (VEGF) [ J 1. Klin Oczna, 2004, 106(4-5) : 682-685.
